title: The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
abstract: Histone deacetylase (HDAC) inhibitors have shown preclinical efficacy in solid tumors, including ovarian cancers. Our group has published that the HDAC inhibitor, romidepsin (FK228) suppresses ovarian cancer cell growth at nanomolar concentrations in vitro. HDAC inhibitors appear to be even more effective when used in combination with other antitumor agents. However, it remains unclear which antitumor agents are best suited for combination therapy. A recent report suggested that aspirin (acetylsalicylic acid, ASA ) is synergistic with HDAC inhibitors in ovarian cancer cells. ASA is a relatively selective inhibitor of cyclooxygenase-1 (COX-1) and has anti-proliferative effects in ovarian cancer cells. The goal of this study was to investigate the impact of ASA on the activity of the HDAC inhibitor, FK228 in COX-1 positive (OVCAR-3) and COX-1 negative (SKOV-3) human ovarian cancer cell lines. The growth inhibitory effects of FK228 were enhanced by ASA in COX-1 positive ovarian cancer cells. In contrast, ASA had no influence on the results of FK228 treatment in COX-1 negative ovarian cancer cells. Upregulation of the cell cycle control protein p21 was induced robustly by FK228 in both cell lines. In the COX-1 positive cells, p21 expression was augmented by the addition of ASA to FK228 treatment. Furthermore, COX-1 siRNA attenuated the effects of combined ASA and FK228 on the levels of p21 expression and the amount of growth inhibition. The additional increase in p21 by ASA in FK228-treated cells was not observed at the promoter or transcriptional levels. However, a significant delay in p21 protein degradation in the presence of ASA and FK228 in COX-1 positive cells was associated with inhibition of proteasome activity. Our study provides a potential rationale for combining ASA with HDAC inhibitors in a subset of ovarian cancers.
authors.affiliation: Department of Obstetrics and Gynecology, Meharry Medical College, Vanderbilt University School of Medicine, Nashville, TN, USA.
authors.forename: Deok-Soo
authors.initials: DS
authors.lastname: Son
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Wilson
authors.forename: Angelika K
authors.initials: AK
authors.lastname: Parl
authors.forename: Dineo
authors.initials: D
authors.lastname: Khabele
mesh_terms: D001241:Aspirin / Q000494:pharmacology*; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism*; D051545:Cyclooxygenase 1 / Q000235:genetics / Q000378:metabolism*; D047630:Depsipeptides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D034622:RNA Interference; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D050759:Cyclin-Dependent Kinase Inhibitor p21; D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; C087123:romidepsin; D051545:Cyclooxygenase 1; D046988:Proteasome Endopeptidase Complex; D001241:Aspirin
references.citation: Cancer Res. 2003 Mar 1;63(5):906-11
references.pmid: 12615701
references.citation: Oncol Rep. 2008 Jul;20(1):219-24
references.pmid: 18575740
references.citation: Nat Rev Drug Discov. 2006 Sep;5(9):769-84
references.pmid: 16955068
references.citation: Cancer Res. 2005 May 1;65(9):3735-44
references.pmid: 15867369
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7
references.pmid: 8265610
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: J Biol Chem. 2006 Sep 29;281(39):29228-35
references.pmid: 16880202
references.citation: Cancer Biol Ther. 2007 May;6(5):795-801
references.pmid: 17387270
references.citation: Nat Rev Genet. 2009 Jan;10(1):32-42
references.pmid: 19065135
references.citation: Surgery. 2004 Aug;136(2):416-25
references.pmid: 15300209
references.citation: Cancer Lett. 2009 Aug 8;280(2):125-33
references.pmid: 19359091
references.citation: Cancer Res. 2007 Jun 1;67(11):5285-92
references.pmid: 17545608
references.citation: Gynecol Oncol. 2008 May;109(2):182-6
references.pmid: 18295319
references.citation: Cell. 2003 Oct 3;115(1):71-82
references.pmid: 14532004
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):435-42
references.pmid: 20142241
references.citation: Mini Rev Med Chem. 2007 Oct;7(10):1062-9
references.pmid: 17979809
references.citation: Surg Clin North Am. 2008 Apr;88(2):285-99, vi
references.pmid: 18381114
references.citation: J Clin Oncol. 2008 Feb 20;26(6):995-1005
references.pmid: 18195328
references.citation: Neoplasia. 2008 Sep;10(9):1021-7
references.pmid: 18714364
references.citation: N Engl J Med. 2004 Dec 9;351(24):2519-29
references.pmid: 15590954
references.citation: Gynecol Oncol. 2004 Apr;93(1):19-26
references.pmid: 15047209
references.citation: Cancer Res. 2006 Mar 1;66(5):2527-31
references.pmid: 16510568
references.citation: Gynecol Oncol. 2009 Jan;112(1):166-70
references.pmid: 18986688
references.citation: Int J Biochem Cell Biol. 2007;39(7-8):1367-74
references.pmid: 17412634
references.citation: Mol Cancer Ther. 2006 Nov;5(11):2606-12
references.pmid: 17088437